Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
These gynecologic cancers share molecular characteristics and often arise from serous cell types. DNA repair biomarkers play a central role in treatment selection.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in FDA labeling.
Defined at the solid tumor level and applicable to Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer and other solid tumor cancers.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. Select a therapy to view the specific approval and eligible tests.
FOLR1 (protein expression)
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High)
PD-L1 (PD-L1 protein expression [Combined Positive Score (CPS) ≥ 1]); deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High); TMB (TMB ≥ 10 mutations per megabase)
RET (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)